Pharmaceutical industry: latest news

Pharmaceutical industry features

Pharmaceutical industry news from aidsmap

More news

Pharmaceutical industry news selected from other sources

  • Merck, GlaxoSmithKline face hepatitis A vaccine shortage amid US outbreaks

    Since March, the CDC’s Division of Viral Hepatitis has identified hepatitis A outbreaks in several cities in California, Michigan and Utah, especially among people who are homeless and people who use drugs. Over the past six months, those ongoing outbreaks have resulted in supply stress for vaccine makers Merck and GSK, which sell U.S.-licensed hepatitis A shots Vaqta and Havrix, respectively.

    15 November 2017 | FiercePharma
  • Danish court invalidates Gilead SPC

    The Danish Maritime and Commercial High Court has invalidated a supplementary protection certificate (SPC) owned by Gilead. On October 26, the court rejected Gilead’s motion for an injunction against generics maker Accord.

    10 November 2017 | Life Sciences Intellectual Property Review
  • Gilead loss of generic HIV drug battle a boost for gay community

    09 November 2017 | The Irish Times
  • Why do some HIV drugs cost so much in the US? Pharma, insurers, advocacy groups and consumers weigh in

    As open enrollment begins November 1, millions of Americans are comparing insurance plans available on the Affordable Care Act insurance marketplace. Prescription copayments and which medications a health plan covers are key considerations for people living with HIV and for those taking regular prescription medications. The cost to the consumer is very different, however, from the price that insurers negotiate with pharmaceutical companies, and the debate around drug pricing has hit national headlines in recent years with cases like EpiPen and Daraprim. Drug pricing is a complicated issue, with pharmaceutical companies on one side, patient activists on the other, and consumers oftentimes stuck somewhere in the middle.

    03 November 2017 | BETA blog
  • GSK and Gilead go head to head as HIV drugs enter new phase

    Gilead Sciences and GlaxoSmithKline are heading for an HIV showdown, pushing rival treatment visions and competing products that are expected to hit the market in the next few months. Gilead is likely to secure the bigger near-term win, as it builds on a 20-year-old strategy of combining three drugs to control the AIDS virus, while GSK is placing a longer bet that its core drug is potent enough to work with just one other.

    02 November 2017 | Reuters
  • MSF Secures Deals For Key Hepatitis C Medicines, Price A Fraction Of Branded Drug

    Médecins Sans Frontières (MSF, Doctors Without Borders) announced today that it has secured deals for two key generic hepatitis C medicines, sofosbuvir and daclatasvir, for as low as US$1.40 per day, or US$120 per 12-week treatment course.

    31 October 2017 | Intellectual Property Watch
  • Gilead HCV drug sales down in 2017 third quarter compared with 2016

    Gilead announced that combined third-quarter sales for Harvoni, Sovaldi, Epclusa and Vosevi were $2.2 billion compared with $3.3 billion the third quarter of 2016, related to fewer patients initiating treatment and increased drug competition.

    31 October 2017 | Healio
  • Health Group Challenges Gilead Patents In The US On Grounds Of Lack Of Novelty

    A health advocacy group today announced that it has challenged a set of United States patents for a hepatitis C medicine. The group says drug maker Gilead Sciences has obtained unmerited patents for sofosbuvir, blocking millions of US patients from affordable treatment.

    26 October 2017 | Intellectual Property Watch
  • HIV pills and new lung drugs keep GSK on track in third-quarter

    GlaxoSmithKline (GSK.L) grew sales 4 percent in the third quarter, helped by demand for new products, keeping it on track to deliver on full-year financial targets as new Chief Executive Emma Walmsley refocuses the drugs pipeline.

    25 October 2017 | Reuters
  • The German CEO Pushing for an Immunotherapy to Treat Cancer and HIV

    Mariola Söhngen, CEO of Mologen, discusses biotech entrepreneurship in Germany and her company’s unique immunotherapy against both cancer and HIV.

    23 October 2017 | Labiotech.eu (blog)
More news


Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.